503
Participants
Start Date
February 19, 2018
Primary Completion Date
April 19, 2019
Study Completion Date
January 13, 2022
HD201
Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.
Herceptin
Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.
Docetaxel
75mg/m2 via i.v. infusion during cycles 1 to 4.
Epirubicin
75 mg/m2 via i.v. infusion during cycles 5-8.
Cyclophosphamide
500 mg/m2 via i.v. infusion during cycles 5-8.
National Institute of Oncology, Budapest
Complex Oncology Center, Plovdiv
University of Debrecen, Debrecen
East Tallinn Central Hospital, Tallinn
Hospital Universitario Virgen Macarena, Seville
Modena Hospital, Modena
Beacon International Specialist Centre, Kuala Lumpur
Maharaj Nakorn Chiang Mai Hospital, Chiang Mai
Hospital Kuala Lumpur, Kuala Lumpur
"GI V. T. Zaycev Institute General and Urgent Surgery of NAMS of Ukraine ", Kharkiv
Centre René Huguenin (Institut Curie), Saint-Cloud
"LLC Vitamed", Moscow
Minsk Clinical Oncological Dispensary, Minsk
S. Khechinashvili University Hospital, Tbilisi
Szpital Specjalistyczny Brzeziny, Brzeziny
Lead Sponsor
Prestige Biopharma Limited
INDUSTRY